InvestorNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Delivering, Well-Positioned in ‘High-Demand’ Market

DarioHealth (NASDAQ: DRIO), a leader in the global digital therapeutics (“DTx”) market, has announced that it is “adding contracts with self-insured employers and national health plans as Amazon and CVS vie to lead value-based, patient-centric virtual healthcare.” According to the announcement, digital healthcare is delivering both better health outcome and also lower costs for the national health-care sector. Dario’s proprietary offering features a user-centric, multichronic condition platform and suite of solutions designed to deliver personalized and dynamic interventions based on data analytics; the platform also includes one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health. The platform provides a turnkey, one-vendor solution for payers, observed DarioHealth. The company has consistently announced new contracts, most recently signing an agreement with a “jumbo” global employer account that represents the increasing penetration of the Dario platform. The announcement also noted that DRIO is delivering on its goal to sign 100 enterprise contracts by the end of year; the company is also reporting a strong balance sheet with $68 million in cash and equivalents as of June 30, 2022, and an additional $25 million of availability on an existing credit facility. DarioHealth is “well positioned and capitalized, signing significant contracts with large clients,” the company stated in the announcement. “The digital therapeutics market is being forced to consolidate with pressure from consumers to deliver healthcare on a value-based system. With Dario’s clinically verified ROI to payers lowering costs for the national healthcare sector, DRIO is clearly delivering in a high-demand market. Investors looking to capitalize on the digital health sector need to put DRIO on their radar.”

To view the full press release, visit https://ibn.fm/Iq2Sh

About DarioHealth Corp.

DarioHealth Corp. is a leading digital therapeutics (DTx) company revolutionizing how people with chronic conditions manage their health through a user-centric, multichronic condition platform. Dario’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company’s user-centric platform offers people continuous and customized care for health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention, and results. Dario provides its highly user rated solutions globally to health plans and other payors, self-insured employers, providers of care and directly to consumers. For more information about the company, please visit www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork